regeneron glp-1 Today at #EASD2025, we announced results from our Phase 2 trial investigating the addition of our antibodies to a receptor agonist to assess its impact on quality of weight loss. Learn Regeneron's GLP-1/GIP obesity drug succeeds

In aiming for a meaningful comparison between type 1 and type 2 diabetes, we sought to minimize age disparities while ensuring a relatively comparable duration of diabetes among participants, which we successfully achieved

Agrawal A, Agrawal S, Cao JN, Su H, Osann K, Gupta S

d , Representative biological processes of differentially expressed genes in neuron, nonneuron and immune cell types

What also clearly emerges is the paucity of data in female animal models or women in very basic aspects of the science of GLP-1gaps that should be urgently mended, given the growing popularity of these medications, especially in women